Healthcare provider profile · identity verified

Paul Sobel, MD

Internal Medicine · RENO, NV · NPI 1861519050

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	816	277
Losartan Potassium	Losartan Potassium	384	133
Amlodipine Besylate	Amlodipine Besylate	368	130
Lisinopril	Lisinopril	355	120
Levothyroxine Sodium	Levothyroxine Sodium	249	76
Hydrochlorothiazide	Hydrochlorothiazide	216	87
Tamsulosin Hcl	Tamsulosin Hcl	210	74
Simvastatin	Simvastatin	177	55
Famotidine	Famotidine	176	71
Metformin Hcl	Metformin Hcl	174	63
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	163	42
Gabapentin	Gabapentin	159	58
Fluticasone Propionate	Fluticasone Propionate	156	48
Atenolol	Atenolol	153	54
Metoprolol Tartrate	Metoprolol Tartrate	145	46
Trazodone Hcl	Trazodone Hcl	133	37
Furosemide	Furosemide	110	40
Glipizide	Glipizide	107	40
Rosuvastatin Calcium	Rosuvastatin Calcium	103	34
Pantoprazole Sodium	Pantoprazole Sodium	100	37
Sertraline Hcl	Sertraline Hcl	100	36
Allopurinol	Allopurinol	96	34
Pravastatin Sodium	Pravastatin Sodium	96	29
Albuterol Sulfate Hfa	Albuterol Sulfate	89	55
Alendronate Sodium	Alendronate Sodium	85	28
Omeprazole	Omeprazole	85	29
Terazosin Hcl	Terazosin Hcl	81	26
Ibuprofen	Ibuprofen	80	32
Hydralazine Hcl	Hydralazine Hcl	68	29
Potassium Chloride	Potassium Chloride	66	25
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	65	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	62	19
Alvesco	Ciclesonide	53	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	52	18
Wixela Inhub	Fluticasone Propion/Salmeterol	52	16
Doxycycline Monohydrate	Doxycycline Monohydrate	49	36
Metoprolol Succinate	Metoprolol Succinate	48	21
Carvedilol	Carvedilol	47	11
Meloxicam	Meloxicam	46	25
Montelukast Sodium	Montelukast Sodium	45	16
Fluoxetine Hcl	Fluoxetine Hcl	44	18
Jardiance	Empagliflozin	44	18
Mirtazapine	Mirtazapine	44	12
Prednisone	Prednisone	44	30
Amoxicillin	Amoxicillin	43	19
Triamcinolone Acetonide	Triamcinolone Acetonide	43	26
Acyclovir	Acyclovir	40	11
Duloxetine Hcl	Duloxetine Hcl	40	15
Lovastatin	Lovastatin	38	13
Finasteride	Finasteride	37	13
Metformin Hcl Er	Metformin Hcl	37	17
Tramadol Hcl	Tramadol Hcl	35	suppressed
Azelastine Hcl	Azelastine Hcl	34	13
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	34	34
Ozempic	Semaglutide	32	suppressed
Humulin N	Insulin Nph Human Isophane	31	15
Colchicine	Colchicine	29	15
Hydrocortisone	Hydrocortisone	29	20
Isosorbide Mononitrate Er	Isosorbide Mononitrate	29	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	11
Propranolol Hcl	Propranolol Hcl	28	suppressed
Clobetasol Propionate	Clobetasol Propionate	27	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	27	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	26	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	26	suppressed
Tizanidine Hcl	Tizanidine Hcl	25	suppressed
Lorazepam	Lorazepam	24	13
Cefadroxil	Cefadroxil	23	20
Celecoxib	Celecoxib	22	suppressed
Chlorthalidone	Chlorthalidone	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	21	suppressed
Humulin R	Insulin Regular, Human	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	suppressed
Warfarin Sodium	Warfarin Sodium	21	suppressed
Fenofibrate	Fenofibrate	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Eliquis	Apixaban	19	suppressed
Naproxen	Naproxen	19	12
Oxycodone Hcl	Oxycodone Hcl	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Fluocinonide	Fluocinonide	17	12
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	14	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Risperidone	Risperidone	14	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	14	suppressed
Victoza 2-Pak	Liraglutide	14	suppressed
Buprenorphine	Buprenorphine	13	suppressed
Erythromycin	Erythromycin Base	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Alprazolam	Alprazolam	11	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Fluorouracil	Fluorouracil	11	11
Ranolazine Er	Ranolazine	11	suppressed
Serevent Diskus	Salmeterol Xinafoate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error